Format

Send to:

Choose Destination
See comment in PubMed Commons below
Urology. 2011 Nov;78(5):1046-50. doi: 10.1016/j.urology.2011.07.1394. Epub 2011 Sep 9.

Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started?

Author information

  • 1Servicio de Urología del Hospital Universitario Virgen de la Victoria, Málaga, España. crmarchal@gmail.com

Abstract

OBJECTIVE:

To study the response to posterior tibial nerve stimulation in patients with overactive bladder refractory to medical treatment.

METHODS:

A cohort of 53 patients were treated by posterior tibial nerve stimulation and followed up for a maximum of 24 months. All patients completed the International Consultation on Incontinence Modular Questionnaire-Short Form quality of life questionnaire and kept a urination diary to record the daytime urination frequency and night-time urination frequency. Urodynamic studies were also conducted.

RESULTS:

At 6 months of follow-up, a cure/improvement rate of 92.4% (49 of 53 cases) had been achieved. Ten patients were given additional treatment and were excluded from subsequent follow-up analysis. At 12 months of follow-up, a cure/improvement rate of 91.69% had been achieved (39 of 43). At 24 months of follow-up, of the 16 patients initially included during the first year, a cure/improvement rate of 62.5% had been achieved (10 of 16). The first sensation of bladder filling had increased by the end of treatment, with differences observed before and after posterior tibial nerve stimulation (P ≤ .001). The average post-treatment bladder capacity had increased by 72.7 mL compared with the initial value (P ≤ .001). At 24 months of follow-up, the group of 16 patients evaluated recorded a significant worsening of night-time urination frequency (P ≤ .05) and quality of life (P ≤ .01).

CONCLUSION:

Posterior tibial nerve stimulation is a good option for the treatment of overactive bladder. In our series, the optimal point to start retreatment would be at 24 months after therapy completion.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21908024
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk